Patents by Inventor Norbert Beier

Norbert Beier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11179810
    Abstract: The disclosure relates to systems and methods for machine-cutting workpieces in plate form or bar form and also to a machine tool, with a laser machining device, and a workpiece support, by which a workpiece to be machined in the laser machining device is received, and with a workpiece moving device, by which the workpiece to be machined is held and moved in relation to the laser machining device, wherein with a machining head a laser beam is directed onto the workpiece to be machined and a clearance or recess is introduced into the workpiece and the clearance is machined with a flow drill and widened to a final size of a borehole.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: November 23, 2021
    Assignee: TRUMPF Werkzeugmaschinen GmbH + Co. KG
    Inventors: Karsten Ruetz, Norbert Beier, Juergen Hohenadel, Simon Reinwald, Florian Jarsch
  • Patent number: 10292949
    Abstract: The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of ß-cell compensation.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: May 21, 2019
    Assignee: Meck Patent GmbH
    Inventors: Norbert Beier, Wolfgang Scholz, Ulrich Betz, Marian Braendle
  • Publication number: 20190030649
    Abstract: The disclosure relates to systems and methods for machine-cutting workpieces in plate form or bar form and also to a machine tool, with a laser machining device, and a workpiece support, by which a workpiece to be machined in the laser machining device is received, and with a workpiece moving device, by which the workpiece to be machined is held and moved in relation to the laser machining device, wherein with a machining head a laser beam is directed onto the workpiece to be machined and a clearance or recess is introduced into the workpiece and the clearance is machined with a flow drill and widened to a final size of a borehole.
    Type: Application
    Filed: October 1, 2018
    Publication date: January 31, 2019
    Inventors: Karsten Ruetz, Norbert Beier, Juergen Hohenadel, Simon Reinwald, Florian Jarsch
  • Publication number: 20170189354
    Abstract: The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of ?-cell compensation.
    Type: Application
    Filed: March 24, 2017
    Publication date: July 6, 2017
    Applicant: Merck Patent GmbH
    Inventors: Norbert BEIER, Wolfgang SCHOLZ, Ulrich BETZ, Marian BRAENDLE
  • Patent number: 8815924
    Abstract: Novel heterocyclic compounds of the formula (I), in which R1, D, W, T and T? have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and conditions, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: August 26, 2014
    Assignee: Merck Patent GmbH
    Inventors: Dieter Dorsch, Rolf Gericke, Werner Mederski, Norbert Beier, Florian Lang
  • Patent number: 8546613
    Abstract: The present invention relates to a compound of formulas I, Ia, Ib and II, wherein R1 to R11 are herein defined.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: October 1, 2013
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Rolf Gericke, Norbert Beier, Florian Lang, Phillipp Lang, Karl Lang
  • Patent number: 8492440
    Abstract: Novel difluorophenyldiacylhydrazide derivatives of the formula I, in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in claim 1, are kinase inhibitors and can be used for the treatment of diseases and complaints such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in any type of fibroses, inflammatory processes, tumours and tumour diseases.
    Type: Grant
    Filed: November 2, 2009
    Date of Patent: July 23, 2013
    Assignee: Merck Patent GmbH
    Inventors: Thomas Fuchss, Ulrich Graedler, Norbert Beier, Rolf Gericke, Florian Lang
  • Patent number: 8431602
    Abstract: Novel heterocyclic compounds of the formula I in which R1, R2, R2?, R2?, R3, R4, R5, R6, R7 and R8 have the meanings indicated in Claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Grant
    Filed: December 23, 2008
    Date of Patent: April 30, 2013
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Stefan Bender, Lars Thore Burgdorf, Ulrich Emde, Norbert Beier, Johannes Gleitz, Christine Charon
  • Patent number: 8420642
    Abstract: Novel heterocyclic compounds of the formula I in which R1, R2, R3, R4 and D have the meanings indicated in Claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Grant
    Filed: August 13, 2008
    Date of Patent: April 16, 2013
    Assignee: Merck Patent GmbH
    Inventors: Lars Thore Burgdorf, Norbert Beier, Johannes Gleitz, Christine Charon, Daniel Cravo
  • Patent number: 8399509
    Abstract: Novel compounds of the formula (I), in which X has the meaning indicated in Patent Claim 1, are suitable as antidiabetics.
    Type: Grant
    Filed: March 17, 2009
    Date of Patent: March 19, 2013
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Christos Tsaklakidis, Norbert Beier
  • Patent number: 8383838
    Abstract: The present invention relates to novel compounds of general formula (I) and uses thereof.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: February 26, 2013
    Assignee: Merck Patent Gesellschaft mit Beschränkter Haftung
    Inventors: Christoph Saal, Lars Burgdorf, Ulrich Emde, Norbert Beier, Johannes Gleitz, Christine Charon
  • Patent number: 8377975
    Abstract: Novel oxadiazole derivatives of the formula (I), in which R, R?, Y, X1, X2 and X3 have the meanings indicated in claim 1, are kinase inhibitors and can be used for the treatment of diseases and conditions such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, in general in all types of fibroses, inflammatory processes, tumours and tumour diseases.
    Type: Grant
    Filed: July 9, 2009
    Date of Patent: February 19, 2013
    Assignee: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Markus Klein, Norbert Beier, Florian Lang
  • Patent number: 8334309
    Abstract: Novel heterocyclic indazole derivatives of the formula (I), in which L, Q, R, X, Y, R3, R4 and R5 have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: December 18, 2012
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Markus Klein, Norbert Beier
  • Patent number: 8278312
    Abstract: Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5, R6 and X7 have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.
    Type: Grant
    Filed: September 13, 2008
    Date of Patent: October 2, 2012
    Assignee: Merck Patent Gesellschaft mit Beschränkter Haftung
    Inventors: Markus Klein, Werner Mederski, Christos Tsaklakidis, Norbert Beier
  • Patent number: 8258151
    Abstract: Novel compounds of the formula I, in which X, Y, R, R?, R1, R1?, R1?, R2, R2?, R2?, R3, R3?, R4, R4? and n have the meanings indicated in Patent Claim 1, are suitable as antidiabetics
    Type: Grant
    Filed: May 25, 2007
    Date of Patent: September 4, 2012
    Assignee: Merck Patent GmbH
    Inventors: Werner Mederski, Norbert Beier, Bertram Cezanne, Rolf Gericke, Markus Klein, Christos Tsaklakidis
  • Patent number: 8236824
    Abstract: Novel heterocyclic compounds of the formula I in which R1, R2, R3, R4, R5, R6, R7, Alk and D have the meanings indicated in claim 1, are activators of glucokinase and can be used for the prevention and/or treatment of Diabetes Typ 1 and 2, obesity, neuropathy and/or nephropathy.
    Type: Grant
    Filed: September 9, 2008
    Date of Patent: August 7, 2012
    Assignee: Merck Patent Gesellschaft mit Beschränkter Haftung
    Inventors: Lars Thore Burgdorf, Norbert Beier, Johannes Gleitz, Ulrich Emde, Christine Charon, Denis Carniato
  • Patent number: 8207210
    Abstract: Novel aminoindazolylurea derivatives of the formula I (I), in which R1, R2, R3, R4, R5, X and Y have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: June 26, 2012
    Assignee: Merck Patent GmbH
    Inventors: Markus Klein, Rolf Gericke, Norbert Beier, Florian Lang
  • Patent number: 8153649
    Abstract: Novel compounds of the formula (I), in which W, T, R1, R2, R3, R4, R5 and R6 have the meanings indicated in Patent Claim (1), are suitable as antidiabetics.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: April 10, 2012
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Markus Klein, Rolf Gericke, Norbert Beier, Bertram Cezanne, Christos Tsaklakidis, Werner Mederski
  • Patent number: 8119675
    Abstract: Novel compounds of the formula I (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R, Q, W, X and Z have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: February 21, 2012
    Assignee: Merck Patent GmbH
    Inventors: Lars Thore Burgdorf, Bertram Cezanne, Markus Klein, Rolf Gericke, Christos Tsaklakidis, Werner Mederski, Norbert Beier
  • Patent number: 8106067
    Abstract: Novel compounds of the formula (I), in which X, Y, R, R1, R1, R1?, R2, R2?, R3, R4, R4?, R5 and n have the meanings indicated in patent claim 1, are suitable as antidiabetics.
    Type: Grant
    Filed: November 17, 2007
    Date of Patent: January 31, 2012
    Assignee: Merck Patent GmbH
    Inventors: Werner Mederski, Norbert Beier, Lars Thore Burgdorf, Rolf Gericke, Markus Klein, Christos Tsaklakidis